deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02920008

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid Leukemia

Sponsor: Astex Pharmaceuticals, Inc.

Conditions Acute Myeloid Leukemia
Interventions Treatment Choice (TC) guadecitabine
Updated 33 times since 2017 Last updated: Jul 31, 2024 Started: Mar 16, 2017 Primary completion: Jan 20, 2020 Completion: Jun 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acute Myeloid Leukemia and is currently completed. Astex Pharmaceuticals, Inc. leads this study, which shows 33 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Jun 2023 · 14 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

33 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2022 — Jun 2023 [monthly]

    Completed PHASE3

▶ Show 28 earlier versions

  1. Oct 2021 — Apr 2022 [monthly]

    Completed PHASE3

  2. Feb 2021 — Oct 2021 [monthly]

    Completed PHASE3

  3. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  4. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  9. May 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  14. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  15. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  16. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  17. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  18. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  19. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  20. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  21. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  22. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  23. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  24. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  25. Jul 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  26. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  27. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE3

  28. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astex Pharmaceuticals, Inc.
Data source: Astex Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus C, Denmark , Akita, Japan , Albuquerque, United States , Barcelona, Spain , Bayonne, France , Birmingham, United Kingdom , Braunschweig, Germany , Bristol, United Kingdom , Bruges, Belgium , Brussels, Belgium and 72 more locations